Skip to main content

Table 2 Pulmonary arterial hypertension-specific treatments used during the study

From: Medium-term health-related quality of life in patients with pulmonary arterial hypertension treated with goal-oriented sequential combination therapy based on exercise capacity

Medication

Baseline

3 months

6 months

12 months

(n = 30)

(n = 30)

(n = 29)

(n = 28)

ERA

0

30 (100%)

29 (100%)

28 (100%)

PDE-5I

0

2 (7%)

23 (79%)

23 (82%)

Epoprostenol i.v.

0

0

0

1 (4%)

  1. ERA Endothelin receptor antagonist, PDE-5I Phosphodiesterase-5 inhibitor, i.v. Intravenous administration
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us